{"id":27792,"date":"2024-12-31T21:00:55","date_gmt":"2024-12-31T15:30:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27792"},"modified":"2025-10-09T17:06:14","modified_gmt":"2025-10-09T11:36:14","slug":"risvodetinib-breakthrough-in-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease","title":{"rendered":"Risvodetinib: A Promising Breakthrough in Parkinson\u2019s Disease Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5bd372d06e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5bd372d06e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\/#Patient_Enrollment_Complete_for_Phase_II_Trial\" >Patient Enrollment Complete for Phase II Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\/#A_Novel_Tablet_Formulation\" >A Novel Tablet Formulation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\/#Encouraging_Phase_II_Data_Presented_at_MDS_Congress\" >Encouraging Phase II Data Presented at MDS Congress<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\/#Looking_Ahead\" >Looking Ahead<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<ul class=\"wp-block-list\">\n<li><em>Inhibikase Therapeutics\u2019 lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment of Parkinson\u2019s disease. Unlike traditional treatments that focus on managing symptoms, Risvodetinib targets the underlying biological mechanisms driving disease progression.<\/em><\/li>\n\n\n\n<li><em>Risvodetinib\u2019s mechanism of action offers the potential for disease modification in Parkinson\u2019s disease patients. By restoring neuroprotective mechanisms through Abl kinase inhibition, Risvodetinib seeks to not only halt disease progression but also reverse functional loss associated with the condition.<\/em><\/li>\n<\/ul>\n\n\n\n<p>The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of risvodetinib in untreated <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-epidemiology-forecast\">Parkinson\u2019s Disease patients<\/a>. With participants randomized across therapeutic doses and placebo groups, safety measures include evaluation of treatment-emergent adverse events, cardiovascular safety, standard laboratory analyses, and monitoring for changes in vision. Early indications suggest promising safety and tolerability profiles, laying a solid foundation for further investigating risvodetinib\u2019s therapeutic efficacy.&nbsp;<\/p>\n\n\n\n<p>Risvodetinib\u2019s mechanism of action, targeting alpha-synuclein aggregate pathology, holds the potential for significant clinical benefit in <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson\u2019s Disease<\/a>. The trial\u2019s secondary endpoints, including measures of motor and non-motor function in the Central and Enteric Nervous Systems, offer comprehensive insights into Risvodetinib\u2019s therapeutic effects. Biomarker analysis using CSF\/plasma assessment and skin biopsy further complement functional assessments, providing a multifaceted approach to evaluating treatment efficacy.<\/p>\n\n\n\n<p>Since the trial started, Inhibikase Therapeutics has been making significant strides in developing risvodetinib (formerly IkT-148009), an innovative oral therapy aimed at altering the course of <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights\">Parkinson\u2019s disease treatment<\/a>. This promising drug, now undergoing Phase II clinical evaluation, seeks to slow or even halt the progression of this debilitating neurodegenerative condition. Here\u2019s a closer look at its development milestones and the encouraging results emerging from the ongoing 201 trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-patient-enrollment-complete-for-phase-ii-trial\"><span class=\"ez-toc-section\" id=\"Patient_Enrollment_Complete_for_Phase_II_Trial\"><\/span>Patient Enrollment Complete for Phase II Trial<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As of June 2024, Inhibikase announced the completion of patient enrollment in its 201 trial (NCT05424276). The study involves 120 participants across 32 sites in the U.S., with an expected total enrollment of 126 to accommodate pre-screened individuals. This trial aims to assess the safety and efficacy of risvodetinib in untreated Parkinson\u2019s patients.<\/p>\n\n\n\n<p>To date, 69 participants have completed dosing, with 32 mild and five moderate adverse events potentially linked to the treatment. Despite these, early data from 25 patients indicated that risvodetinib successfully stabilized disease progression and symptom severity, offering hope to the Parkinson\u2019s community. The company plans to share top-line results in the fourth quarter of 2024, with Phase III discussions with the FDA anticipated by year-end.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-novel-tablet-formulation\"><span class=\"ez-toc-section\" id=\"A_Novel_Tablet_Formulation\"><\/span>A Novel Tablet Formulation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In August 2024, Inhibikase introduced a breakthrough in drug delivery with a newly designed tablet formulation of risvodetinib. This formulation enhances drug exposure, nearly doubling steady-state levels compared to the current capsule form used in the trial. This innovation has the potential to lower required doses, improving both safety and tolerability.<\/p>\n\n\n\n<p>Moreover, the smaller tablet size addresses the swallowing difficulties often faced by Parkinson\u2019s patients, ensuring greater patient comfort and compliance. This novel formulation is expected to be rolled out in a planned 12-month extension of the ongoing trial, further advancing the treatment\u2019s potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-encouraging-phase-ii-data-presented-at-mds-congress\"><span class=\"ez-toc-section\" id=\"Encouraging_Phase_II_Data_Presented_at_MDS_Congress\"><\/span>Encouraging Phase II Data Presented at MDS Congress<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In October 2024, new unblinded data from the 201 trial showcased risvodetinib\u2019s promise. A once-daily 200 mg dose demonstrated safety and efficacy in improving motor function and easing daily activities for untreated Parkinson\u2019s patients. These findings stemmed from 11 participants who continued in the trial following a temporary FDA-mandated clinical hold in 2023, which was lifted in January 2024.<\/p>\n\n\n\n<p>Risvodetinib was shown to reach steady levels in the body within five days without serious side effects, regardless of the dose tested (50, 100, or 200 mg). While the dataset remains small, these preliminary results were described as &#8220;cautiously encouraging&#8221; by Dr. Milton Werner, President and CEO of Inhibikase, during his presentation at the Movement Disorders Society (MDS) congress in Copenhagen.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-looking-ahead\"><span class=\"ez-toc-section\" id=\"Looking_Ahead\"><\/span>Looking Ahead<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The progress of risvodetinib in Phase II trials underscores Inhibikase\u2019s commitment to developing transformative therapies for Parkinson\u2019s disease. With patient enrollment complete, a novel formulation ready for implementation, and preliminary data showing promising outcomes, risvodetinib could become a game-changer in Parkinson\u2019s treatment.<\/p>\n\n\n\n<p>The company now analyzes top-line data and plans pivotal Phase III trials. As we await further results, risvodetinib remains a beacon of hope for those living with Parkinson\u2019s, representing a step closer to modifying the course of this challenging disease.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-30639\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1760009743206\"><strong class=\"schema-faq-question\"><strong>How does Risvodetinib work in Parkinson\u2019s disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Risvodetinib functions by inhibiting Abl kinase, which plays a role in the aggregation of alpha-synuclein, a protein implicated in Parkinson\u2019s disease. By targeting this pathway, Risvodetinib seeks to restore neuroprotective mechanisms and potentially halt or reverse disease progression.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760009750920\"><strong class=\"schema-faq-question\"><strong>What is the current status of Risvodetinib&#8217;s clinical trials?<\/strong><\/strong> <p class=\"schema-faq-answer\">As of June 2024, Inhibikase Therapeutics completed patient enrollment for the Phase II 201 Trial (NCT05424276), involving 120 participants across 32 U.S. sites. This randomized, placebo-controlled study aims to evaluate the safety, tolerability, and clinical efficacy of Risvodetinib in untreated Parkinson\u2019s disease patients.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760009761332\"><strong class=\"schema-faq-question\"><strong>What are the primary and secondary endpoints of the Phase II trial?<\/strong><\/strong> <p class=\"schema-faq-answer\">The trial&#8217;s primary endpoints focus on assessing treatment-emergent adverse events and cardiovascular safety. Secondary endpoints include evaluating motor and non-motor functions in both the central and enteric nervous systems to gauge the drug&#8217;s broader therapeutic effects.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of risvodetinib in untreated Parkinson\u2019s Disease patients. With participants randomized across therapeutic doses and placebo groups, safety measures include evaluation of treatment-emergent adverse events, cardiovascular safety, standard laboratory analyses, and monitoring for changes in vision. Early indications suggest promising safety and tolerability profiles, laying [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":27795,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[22059,22060,22061,16778,19134,19133,19131],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-27792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aan","tag-aan-2024","tag-aan-2024-conference","tag-parkinsons-disease-4","tag-parkinsons-disease-clinical-trials","tag-parkinsons-disease-pipeline","tag-parkinsons-disease-treatment","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Risvodetinib Breakthrough in Parkinson\u2019s Disease | AAN 2024<\/title>\n<meta name=\"description\" content=\"The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of Risvodetinib in untreated PD patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Risvodetinib Breakthrough in Parkinson\u2019s Disease | AAN 2024\" \/>\n<meta property=\"og:description\" content=\"The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of Risvodetinib in untreated PD patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-31T15:30:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-09T11:36:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/26125048\/risvodetinib-breakthrough-in-parkinsons-disease.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Risvodetinib Breakthrough in Parkinson\u2019s Disease | AAN 2024","description":"The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of Risvodetinib in untreated PD patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease","og_locale":"en_US","og_type":"article","og_title":"Risvodetinib Breakthrough in Parkinson\u2019s Disease | AAN 2024","og_description":"The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of Risvodetinib in untreated PD patients.","og_url":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-31T15:30:55+00:00","article_modified_time":"2025-10-09T11:36:14+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/26125048\/risvodetinib-breakthrough-in-parkinsons-disease.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease","url":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease","name":"Risvodetinib Breakthrough in Parkinson\u2019s Disease | AAN 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/26125048\/risvodetinib-breakthrough-in-parkinsons-disease.png","datePublished":"2024-12-31T15:30:55+00:00","dateModified":"2025-10-09T11:36:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"The ongoing 201 Trial evaluates the safety, tolerability, and clinical benefit of Risvodetinib in untreated PD patients.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009743206"},{"@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009750920"},{"@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009761332"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/26125048\/risvodetinib-breakthrough-in-parkinsons-disease.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/26125048\/risvodetinib-breakthrough-in-parkinsons-disease.png","width":466,"height":284,"caption":"risvodetinib-breakthrough-in-parkinsons-disease"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009743206","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009743206","name":"How does Risvodetinib work in Parkinson\u2019s disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Risvodetinib functions by inhibiting Abl kinase, which plays a role in the aggregation of alpha-synuclein, a protein implicated in Parkinson\u2019s disease. By targeting this pathway, Risvodetinib seeks to restore neuroprotective mechanisms and potentially halt or reverse disease progression.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009750920","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009750920","name":"What is the current status of Risvodetinib's clinical trials?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"As of June 2024, Inhibikase Therapeutics completed patient enrollment for the Phase II 201 Trial (NCT05424276), involving 120 participants across 32 U.S. sites. This randomized, placebo-controlled study aims to evaluate the safety, tolerability, and clinical efficacy of Risvodetinib in untreated Parkinson\u2019s disease patients.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009761332","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/risvodetinib-breakthrough-in-parkinsons-disease#faq-question-1760009761332","name":"What are the primary and secondary endpoints of the Phase II trial?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The trial's primary endpoints focus on assessing treatment-emergent adverse events and cardiovascular safety. Secondary endpoints include evaluating motor and non-motor functions in both the central and enteric nervous systems to gauge the drug's broader therapeutic effects.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/26125048\/risvodetinib-breakthrough-in-parkinsons-disease-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAN 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAN 2024 Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AAN<\/span>","<span class=\"advgb-post-tax-term\">AAN 2024<\/span>","<span class=\"advgb-post-tax-term\">AAN 2024 Conference<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Dec 31, 2024","modified":"Updated on Oct 9, 2025"},"absolute_dates_time":{"created":"Posted on Dec 31, 2024 9:00 pm","modified":"Updated on Oct 9, 2025 5:06 pm"},"featured_img_caption":"risvodetinib-breakthrough-in-parkinsons-disease","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27792"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27792\/revisions"}],"predecessor-version":[{"id":33641,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27792\/revisions\/33641"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27795"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27792"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27792"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}